Channelopathies & Periodic Paralysis
Skeletal muscle channelopathies are a group of rare inherited disorders caused by pathogenic variants in genes encoding voltage-gated ion channels of the sarcolemma. They produce two cardinal phenotypes: myotonia (delayed muscle relaxation after contraction) and periodic paralysis (episodic flaccid weakness). The combined minimum point prevalence of all skeletal muscle channelopathies is approximately 2 per 100,000. Most follow autosomal dominant inheritance, with the notable exception of Becker myotonia congenita (autosomal recessive). Although the disorders are rare, they carry significant morbidity—including life-threatening cardiac arrhythmias in Andersen-Tawil syndrome and progressive fixed myopathy in long-standing periodic paralysis—and they are treatable once recognized. Diagnostic delays of 1 to 32 years remain common, driven by the protean nature of symptoms, misdiagnosis as fibromyalgia or chronic pain, and limited familiarity with these conditions.
Bottom Line
- Periodic paralysis (PP): Episodic flaccid weakness without sensory loss or altered consciousness; hypokalemic PP (CACNA1S, SCN4A) has prolonged attacks triggered by carbohydrate-rich meals and rest after exercise; hyperkalemic PP (SCN4A) has shorter attacks triggered by potassium-rich foods, fasting, and cold
- Andersen-Tawil syndrome (KCNJ2): Triad of periodic paralysis, cardiac arrhythmias (U waves, prolonged QTc/QUc, bidirectional ventricular tachycardia), and dysmorphic features; a screening ECG is insufficient—Holter monitoring is required for cardiac risk stratification
- Non-dystrophic myotonias: Myotonia congenita (CLCN1) exhibits the warm-up phenomenon and muscle hypertrophy; paramyotonia congenita (SCN4A) displays paradoxical myotonia that worsens with repetition and cold; sodium channel myotonias (SCN4A) include fluctuans and permanens subtypes
- Diagnosis: Genetic testing is the diagnostic standard; EMG shows myotonic discharges between attacks and electrical silence during attacks; provocative exercise tests (short and long) remain useful for classifying subtypes and resolving variants of uncertain significance
- Treatment: Dichlorphenamide is the only FDA-approved medication for primary periodic paralysis; acetazolamide, trigger avoidance, and dietary modification are mainstays of chronic prevention; mexiletine is first-line for myotonia; acute hypokalemic attacks require potassium supplementation
- Fixed myopathy: Progressive permanent weakness and intramuscular fat replacement occur in long-standing periodic paralysis and severe myotonia congenita, even in patients who have few or no episodic attacks
Pathophysiology
Ion Channel Physiology
Skeletal muscle excitability depends on the coordinated function of sarcolemmal ion channels. Voltage-gated chloride channels (ClC-1, encoded by CLCN1) are homodimers that maintain the resting membrane potential and contribute to repolarization; they carry approximately 80% of resting membrane conductance in skeletal muscle. Voltage-gated sodium channels (Nav1.4, encoded by SCN4A) spread depolarization along the sarcolemma. L-type calcium channels (Cav1.1, encoded by CACNA1S) serve as voltage sensors for excitation-contraction coupling. Inward rectifier potassium channels (Kir2.1, encoded by KCNJ2) stabilize the resting membrane potential and are expressed in skeletal muscle, cardiac muscle, brain, and bone.
Mechanisms of Disease
- Chloride channel (CLCN1) — loss of function: Reduced chloride conductance lowers the depolarization threshold, producing sarcolemmal hyperexcitability and myotonia
- Sodium channel (SCN4A) — gain of function: Defective fast inactivation produces persistent sodium current; with repetitive stimulation and T-tubular potassium accumulation, persistent depolarization inactivates all sodium channels, causing fiber inexcitability (hyperkalemic PP). Some SCN4A variants cause enhanced activation or impaired slow inactivation, producing myotonia (paramyotonia congenita, sodium channel myotonia)
- Sodium channel (SCN4A) — loss of function: Gating pore leakage current causes paradoxical depolarization with low extracellular potassium, leading to fiber inexcitability (hypokalemic PP type 2)
- Calcium channel (CACNA1S) — gating pore leak: Similar gating pore leakage mechanism to SCN4A loss-of-function variants, producing hypokalemic PP type 1
- Potassium channel (KCNJ2) — loss of function: Abnormal depolarization from reduced inward rectifier current causes myofiber inexcitability (Andersen-Tawil syndrome); Kir2.1 expression in cardiac tissue explains the associated arrhythmias
Periodic Paralysis
The periodic paralyses are rare autosomal dominant disorders characterized by repeated episodes of flaccid weakness without sensory loss, urinary retention, or altered consciousness. During attacks, affected limbs are areflexic. Weakness ranges from subtle functional impairment to complete flaccid paralysis. Attacks may last minutes to days depending on the subtype. All forms of periodic paralysis can lead to progressive fixed proximal weakness (permanent myopathy) after years of disease, even in patients whose episodic attacks are infrequent.
Hypokalemic Periodic Paralysis
Hypokalemic PP is the most common form of primary periodic paralysis, caused by variants in CACNA1S (type 1, ~60%) or SCN4A (type 2, ~20%). Approximately 20–30% of patients with hypokalemic PP have negative genetic testing. Onset typically occurs between ages 5 and 35 years. Attacks are prolonged, often lasting hours to days, and can be severe enough to prevent ambulation.
Hypokalemic PP: Triggers and Features
- Triggers: Carbohydrate-rich or sugar-rich meals, rest after vigorous exercise, emotional or physical stress (epinephrine-mediated hypokalemia), alcohol, diuretics, vomiting, diarrhea, licorice ingestion
- Ictal potassium: Low (<3.5 mEq/L)
- Attack duration: Typically >2 hours; may last up to several days
- Myotonia: Absent (distinguishes from hyperkalemic PP)
- Fixed weakness: Progressive limb-girdle myopathy may develop even without discrete paralytic episodes; a 3-year follow-up study of CACNA1S patients showed increased fatty muscle replacement in 27 of 37 patients, including 8 who had no attacks during follow-up
Thyrotoxic Hypokalemic Periodic Paralysis
Thyrotoxic periodic paralysis (TPP) is a secondary form of hypokalemic PP occurring in the setting of hyperthyroidism. It predominantly affects men of Asian or Hispanic descent. Clinical features are identical to primary hypokalemic PP, but TPP resolves with normalization of thyroid function. Thyroid function testing should be performed in all patients presenting with hypokalemic episodic weakness. Management includes cautious potassium supplementation (risk of rebound hyperkalemia as potassium redistributes intracellularly), nonselective beta-blockers to prevent recurrence, and definitive treatment of hyperthyroidism.
Hyperkalemic Periodic Paralysis
Hyperkalemic PP is caused by gain-of-function variants in SCN4A, with symptom onset typically in the first decade of life. Attacks are shorter than in hypokalemic PP, usually lasting minutes to approximately 1 hour. Myotonia frequently coexists (paramyotonia) and may be the predominant symptom between attacks. Episode frequency increases from onset through age 50, after which it typically decreases. Fixed proximal weakness may develop after age 40.
Hyperkalemic PP: Triggers and Features
- Triggers: Potassium-rich foods (fruit, potatoes, fruit juice), prolonged fasting, skipping meals, cold exposure, rest after exercise, alcohol, emotional stress
- Ictal potassium: >5 mEq/L or ≥1.5 mEq/L above interattack baseline; CK elevated 5–10× normal during attacks
- Attack duration: Typically <2 hours
- Myotonia: Moderate; worsens with exercise (paramyotonia) and cold; may coexist as a combined hyperkalemic PP/paramyotonia congenita phenotype
- SCN4A variant pleiotropy: The same gene can produce hyperkalemic PP, paramyotonia congenita, sodium channel myotonia, or congenital myasthenic syndrome depending on the specific variant; some patients carry additive variants, each insufficient alone but collectively pathogenic
Andersen-Tawil Syndrome
Andersen-Tawil syndrome (ATS) is an autosomal dominant disorder caused by loss-of-function variants in KCNJ2, encoding the inward rectifier potassium channel Kir2.1. The classic triad includes periodic paralysis, cardiac arrhythmias, and dysmorphic features—though the phenotype is highly variable, and approximately 10% of patients lack dysmorphic features. De novo variants account for half of cases; a negative family history does not exclude the diagnosis. When taking a family history, clinicians should ask about all ATS manifestations (not just weakness) and consider reviewing family photographs for subtle dysmorphic features.
Andersen-Tawil Syndrome: Cardiac Risk
- ECG findings: Enlarged U waves, ventricular ectopy, prolonged QTc or QUc intervals; however, a normal screening ECG does NOT exclude cardiac involvement
- Arrhythmias: Bidirectional ventricular tachycardia (highly characteristic), polymorphic VT, long QT syndrome; syncope in ~25% of patients; ~13% require a cardiac pacemaker or defibrillator
- Holter monitoring is mandatory: Initial cardiac presentation occurred in 5 of 52 patients in one cohort, all with normal QT/QU intervals on ECG but abnormal Holter monitoring; screening ECG alone is insufficient for cardiac risk stratification
- Cardiology referral: All patients require ongoing cardiac care; avoid QT-prolonging medications; beta-blockers, flecainide, or amiodarone may be used for arrhythmia management
- Echocardiography: Required at baseline, as structural abnormalities may exist (typically mild)
Dysmorphic features include micrognathia (most common), short stature, scoliosis, hypertelorism, low-set ears, clinodactyly, and syndactyly. Dysmorphic features are absent in ~10% and mild in ~33% of patients. Neurocognitive manifestations (executive dysfunction, memory impairment, impaired processing speed) have been reported in 17% of patients, particularly those with onset before age 10, dysmorphic features, and more severe weakness. Episodic weakness in ATS is most commonly associated with hypokalemia but may resemble hyperkalemic PP in some patients; potassium may also be normal during attacks.
Comparison of Periodic Paralysis Subtypes
| Feature | Hypokalemic PP | Hyperkalemic PP | Andersen-Tawil Syndrome |
|---|---|---|---|
| Gene (channel) | CACNA1S (Ca2+), SCN4A (Na+) | SCN4A (Na+) | KCNJ2 (K+ inward rectifier) |
| Inheritance | Autosomal dominant | Autosomal dominant | Autosomal dominant (~50% de novo) |
| Age of onset | 5–35 years | <20 years (typically first decade) | 2–18 years |
| Typical triggers | Carbohydrates, rest after exercise, stress, alcohol | K+-rich foods, fasting, cold, rest after exercise | Variable (exercise and rest after exercise) |
| Attack duration | >2 hours (up to days) | <2 hours | 1–36 hours |
| K+ during attack | Low | High or normal | Variable (usually low) |
| Maximum weakness severity | Severe | Mild to severe | Moderate |
| Myotonia | Absent | Moderate (paramyotonia) | Absent |
| Cardiac involvement | None | None | Long QT, U waves, bidirectional VT |
| Dysmorphic features | None | None | Micrognathia, clinodactyly, scoliosis, hypertelorism |
| Fixed myopathy | Yes (can occur without attacks) | Yes (after age 40) | Yes (~25% of patients) |
Non-Dystrophic Myotonias
The non-dystrophic myotonias are channelopathies characterized by myotonia (delayed muscle relaxation after voluntary contraction) without the multisystem features of myotonic dystrophy (no cataracts, cardiac conduction abnormalities, endocrine dysfunction, or cognitive impairment). Patients frequently present with muscle stiffness, pain, and fatigue, though they may not volunteer stiffness as a complaint when it is long-standing. Diagnostic delays of 1 to 32 years are common.
Myotonia Congenita (CLCN1)
Myotonia congenita results from loss-of-function variants in the chloride channel gene CLCN1 and has two forms:
| Feature | Thomsen Disease (AD) | Becker Disease (AR) |
|---|---|---|
| Inheritance | Autosomal dominant | Autosomal recessive |
| Onset | Infancy or early childhood | Later childhood; typically more severe |
| Severity | Milder | More severe |
| Muscle hypertrophy | Present (athletic appearance) | Present; more pronounced |
| Warm-up phenomenon | Yes | Yes |
| Transient weakness | Rare | Yes (at onset of activity); may present as toe walking and leg weakness in children |
| Fixed weakness | Rare | May develop over time |
Key features of myotonia congenita include the warm-up phenomenon (myotonia improves with repeated contraction), diffuse muscle hypertrophy resulting from the involuntary "exercise" of myotonic contractions, and the absence of extramuscular manifestations. Children may present with leg myotonia described as difficulty running, frequent falls, or an unusual gait. Pregnancy can aggravate myotonia and unmask previously undiagnosed autosomal dominant chloride channelopathies.
Paramyotonia Congenita (SCN4A)
Paramyotonia congenita is an autosomal dominant sodium channelopathy characterized by paradoxical myotonia—myotonia that worsens rather than improves with repeated activity. Cold exposure dramatically exacerbates symptoms. There is no muscle atrophy or hypertrophy. Symptoms typically begin in childhood, though early signs may be present at birth.
- Ocular paramyotonia: Repeated eye closure produces increasing stiffness until the patient cannot open the eyes more than a slit; lid-lag phenomenon is present
- Cold sensitivity: Muscle stiffness and transient weakness worsen markedly with cold exposure
- Overlap with hyperkalemic PP: Potassium ingestion and cold can trigger transient weakness; some patients have combined paramyotonia/hyperkalemic PP phenotype
Sodium Channel Myotonias (SCN4A)
Sodium channel myotonias are autosomal dominant disorders caused by various SCN4A gain-of-function variants. Myotonia occurs without periodic paralysis. The phenotype ranges from mild intermittent fluctuating stiffness (myotonia fluctuans) to severe continuous stiffness with generalized muscle hypertrophy (myotonia permanens). Muscle stiffness worsens after exercise or ingestion of potassium-rich foods. Neonatal presentations include episodic laryngospasm responsive to sodium channel blockers, stridor, and gasping episodes. Short exercise testing shows pattern III (no CMAP decrement).
Distinguishing Chloride From Sodium Channelopathies
- Warm-up phenomenon (myotonia improves with repetition) → chloride channelopathy
- Paradoxical myotonia (worsens with repetition) → sodium channelopathy
- Transient weakness at activity onset → recessive chloride channelopathy (Becker)
- Muscle hypertrophy → chloride channelopathy or severe sodium channel myotonia
- Cold-worsened stiffness → sodium channelopathy
- Muscle pain → sodium channelopathy
- Facial stiffness, extraocular myotonia, transient diplopia → sodium channelopathy
Diagnostic Evaluation
Genetic Testing
Multigene panel testing is the diagnostic standard for skeletal muscle channelopathies. Commercially available neuromuscular panels include CLCN1, SCN4A, CACNA1S, KCNJ2, and RYR1. When panel testing is negative or identifies a variant of uncertain significance, familial segregation analysis, provocative exercise testing, and in vitro functional channel studies can clarify pathogenicity. If comprehensive panel testing is negative, whole-exome or whole-genome sequencing should be considered, as recently identified genes (MCM3P, ATP1A2) are not included in standard panels.
Electrodiagnostic Testing
| Test | Findings | Clinical Utility |
|---|---|---|
| Needle EMG (between attacks) | Myotonic discharges (waxing and waning, 40–100 Hz, "dive bomber" sound) in proximal and distal muscles; may be present in hyperkalemic PP without clinical myotonia (latent myotonia) | Supports channelopathy diagnosis; distinguish from fibrillation potentials to avoid misdiagnosis as motor neuron disease |
| Needle EMG (during attacks) | Electrical silence (no insertional or voluntary activity) in affected muscles | Confirms that weakness is due to sarcolemmal inexcitability, not upper motor neuron or structural cause |
| Short exercise test | Pattern I (progressive CMAP decrement without recovery): paramyotonia congenita; Pattern II (transient CMAP decrement >20% after exercise, then recovery): myotonia congenita; Pattern III (no decrement): sodium channel myotonia | Subtype classification; can clarify pathogenicity of variants of uncertain significance; performed with warming and cooling protocols |
| Long exercise test (McManis) | CMAP amplitude decrement >40% or area decrement >50% post-exercise | Sensitivity 64–75% for primary PP; a negative test does not exclude the diagnosis |
Additional Investigations
- Serum CK: Normal or mildly elevated between attacks; elevated 5–10× during hyperkalemic PP attacks
- Serum potassium during attacks: Helps classify the type of periodic paralysis; obtain urgently if an attack is observed
- Thyroid function tests: Mandatory in all patients with episodic weakness to exclude thyrotoxic periodic paralysis
- ECG and Holter monitoring: Required in all patients with suspected periodic paralysis; essential for Andersen-Tawil syndrome—Holter monitoring detects arrhythmias missed by screening ECG
- Echocardiography: Baseline imaging in suspected Andersen-Tawil syndrome
- Muscle MRI: Can identify intramuscular fat accumulation even in patients without fixed clinical weakness; distinguishes reversible edema from irreversible fatty replacement; increasingly useful for guiding and assessing treatment
- Muscle biopsy: Not useful for channelopathy diagnosis (findings are nonspecific); reserve for exclusion of metabolic myopathies or structural myopathies
Conditions Mimicking Myotonic Discharges on EMG
- Myotonic discharges without clinical myotonia occur in inflammatory myopathies, Pompe disease, toxic myopathies (statins, colchicine), centronuclear/myotubular myopathy, myofibrillar myopathy, hypothyroidism, amyloid myopathy, caveolinopathy, and MuSK myasthenia
- Myotonic discharges can be mistaken for fibrillation potentials and positive sharp waves, leading to erroneous diagnosis of motor neuron disease
- Presence of extramuscular features (cataracts, cardiac conduction defects, cognitive impairment, ptosis) should prompt evaluation for myotonic dystrophy rather than non-dystrophic myotonia
Treatment
Acute Attack Management
| Intervention | Hypokalemic PP | Hyperkalemic PP | Andersen-Tawil Syndrome |
|---|---|---|---|
| Behavioral | Mild exercise at attack onset | Mild exercise at attack onset | Mild exercise at attack onset |
| Oral potassium | 0.2–0.4 mEq/kg q30min (max 200–250 mEq/day) | Not indicated | If K+ low: 0.2–0.4 mEq/kg q30min |
| IV potassium | 40 mEq/L in 5% mannitol, max 20 mEq/hr (if unable to take PO) | Not indicated | If K+ low and unable to take PO |
| Oral carbohydrate | Not indicated | Up to 2 g/kg | Not typically indicated |
| Inhaled beta-agonist | Not indicated | Salbutamol 2 × 100 mcg metered inhalations | Not typically indicated |
| IV calcium gluconate | Not indicated | 0.5–2 g if severe with high K+ | Not typically indicated |
Acute Treatment Precautions
- IV potassium in hypokalemic PP: Administer in 5% mannitol, NOT in glucose or saline solutions (glucose worsens hypokalemia; saline provides sodium load); do not exceed 200–250 mEq/day
- Thyrotoxic PP: Cautious potassium supplementation due to risk of rebound hyperkalemia as potassium redistributes intracellularly once the attack resolves; add nonselective beta-blockers and treat hyperthyroidism definitively
- Andersen-Tawil syndrome: Cardiac monitoring during acute treatment; avoid QT-prolonging agents
- Do NOT give potassium to patients with hyperkalemic PP—it can worsen paralysis and cause dangerous hyperkalemia
Chronic Prevention of Periodic Paralysis
Dichlorphenamide (Keveyis/Ormalvi) is the only FDA-approved medication for primary periodic paralysis. A randomized, placebo-controlled trial demonstrated significant reduction in attack frequency, severity, and duration in both hypokalemic and hyperkalemic PP. Dosing is 50–200 mg/day in divided doses. Acetazolamide (125–1000 mg/day in divided doses) is the most widely used carbonic anhydrase inhibitor, though it lacks formal FDA approval for this indication. Both agents carry risks of metabolic acidosis, hypokalemia, nephrolithiasis, and paresthesias.
- Hypokalemic PP: Low-salt, low-carbohydrate diet; avoid alcohol; maintenance oral potassium (10–20 mEq up to 3 times daily); potassium-sparing diuretics (triamterene, spironolactone, eplerenone) as adjuncts
- Hyperkalemic PP: Avoid potassium-rich foods; hydrochlorothiazide (25–50 mg/day) to lower serum potassium; carbonic anhydrase inhibitors for attack prevention
- Andersen-Tawil syndrome: Treatment follows the pattern of the predominant ictal potassium level; acetazolamide and dichlorphenamide reduce weakness episodes; ongoing cardiac management is essential
Treatment of Myotonia
| Medication | Dosing | Key Adverse Effects | Monitoring |
|---|---|---|---|
| Mexiletine | Start 150 mg BID; titrate to 200–300 mg TID | GI distress, cardiac dysrhythmia, tremor, ataxia | LFTs, ECG at baseline, 1 month, then annually |
| Lamotrigine | Start 25 mg/day; titrate slowly to 300 mg/day | Headache, fatigue, skin rash (slow titration required) | LFTs, renal function |
| Ranolazine | 500–1000 mg BID | GI distress, dizziness, QT prolongation, vasovagal syncope | Renal function; annual ECG |
| Carbamazepine | 20 mg/kg/day divided TID | Rash, agranulocytosis, hepatotoxicity | LFTs, CBC, TSH; HLA-B*1502 testing in patients of Asian descent |
| Acetazolamide | 125 mg BID; titrate to 250 mg TID | GI distress, hypokalemia, paresthesia, nephrolithiasis | Electrolytes, LFTs, CBC |
Mexiletine is supported by the strongest evidence from multiple randomized controlled trials. A 2024 phase 3 head-to-head trial (mexiletine vs. lamotrigine) demonstrated that lamotrigine reduced stiffness by a comparable amount, providing an important alternative—particularly for women of childbearing age, as lamotrigine has a more favorable pregnancy safety profile. Dantrolene is emerging as an adjunctive treatment for severe myotonic presentations including apnea, laryngospasm, and myotonic crisis with severe limb stiffness.
Medications to Avoid in Channelopathies
- Succinylcholine: Depolarizing neuromuscular blocker that can induce masseter spasm, opisthotonus, and life-threatening ventilatory compromise in myotonia congenita—use non-depolarizing agents for anesthesia
- Beta-adrenergic agonists and antagonists: Can aggravate myotonia
- QT-prolonging medications: Avoid in Andersen-Tawil syndrome due to risk of fatal arrhythmias
- Acetazolamide in ATP1A2 variants: Causes metabolic acidosis that increases leak current through Na/K ATPase, potentially worsening periodic paralysis; use potassium supplementation or potassium-sparing diuretics instead
Fixed Myopathy and Long-Term Outcomes
Progressive, permanent proximal weakness develops in a significant proportion of patients with long-standing periodic paralysis. Muscle MRI studies demonstrate intramuscular fat accumulation that correlates with fixed weakness, with anterior thigh and posterior calf muscles most affected in SCN4A variants, and posterior thigh and posterior calf muscles more affected in KCNJ2 variants. Critically, fatty replacement can progress even in patients without discrete paralytic episodes, suggesting that the disease process involves more than ictal muscle damage alone. Whether rigorous attack prevention modifies the rate of progressive myopathy remains unknown. Fixed weakness also occurs in approximately 25% of patients with Andersen-Tawil syndrome and in severe Becker myotonia congenita. No disease-modifying therapies currently exist. Regular strength monitoring and physical therapy are recommended for all patients with chronic channelopathies.
Newer Genes and Emerging Directions
- RYR1 variants: Rarely cause atypical periodic paralysis with later onset (ages 18–34), myalgias, and muscle cramps; now included in standard periodic paralysis panels
- MCM3P variants: Very rare cause of late-onset periodic paralysis with features resembling hypokalemic PP; involved in mRNA export; responsive to acetazolamide
- ATP1A2 variants: Gating pore leak current through Na/K ATPase produces hypokalemic PP; acetazolamide is contraindicated; potassium supplementation and potassium-sparing diuretics are preferred
- Mutation-specific therapy: In vitro studies are identifying genotype-specific treatment responses (e.g., flecainide efficacy in certain SCN4A variants), moving toward personalized pharmacotherapy
- Muscle MRI as biomarker: Longitudinal studies are evaluating whether treatment responsiveness can be tracked by changes in intramuscular fat fraction, with potential applications in clinical trial design
- Gene therapy: Under investigation as a potential disease-modifying approach; no clinical trials yet in skeletal muscle channelopathies
References
- Kushlaf H. Muscle channelopathies and rhabdomyolysis. Continuum (Minneap Minn) 2025;31(5):1409–1436.
- Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol 2015;5(2):761–790.
- Vivekanandam V, Jaibaji R, Sud R, et al. Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing. Neuromuscul Disord 2023;33(3):270–273.
- Stunnenberg BC, LoRusso S, Arnold WD, et al. Guidelines on clinical presentation and management of nondystrophic myotonias. Muscle Nerve 2020;62(4):430–444.
- Statland JM, Bundy BN, Wang Y, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 2012;308(13):1357–1365.
- Sansone VA, Burge J, McDermott MP, et al. Randomized, placebo-controlled trials of dichlorophenamide in periodic paralysis. Neurology 2016;86(15):1408–1416.
- Vivekanandam V, Manniko R, Skorupinska I, et al. Andersen-Tawil syndrome: deep phenotyping reveals significant cardiac and neuromuscular morbidity. Brain 2022;145(6):2108–2120.
- Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve 2018;57(4):522–530.
- Vivekanandam V, Suetterlin K, Matthews E, et al. Muscle MRI in periodic paralysis shows myopathy is common and correlates with intramuscular fat accumulation. Muscle Nerve 2023;68(4):439–450.
- Holm-Yildiz S, Krag T, Witting N, et al. Hypokalemic periodic paralysis: a 3-year follow-up. Dtsch Z Nervenheilkd 2023;270(12):6057–6063.
- Andersen G, Hedermann G, Witting N, et al. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain 2017;140(9):2295–2305.
- Matthews E, Neuwirth C, Jaffer F, et al. Atypical periodic paralysis and myalgia: RYR1 variants. Neurology 2018;90(5):e412–e418.
- Tan SV, Matthews E, Barber M, et al. Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies. Ann Neurol 2011;69(2):328–340.
- Sansone V, Tawil R. Management and treatment of Andersen-Tawil syndrome (ATS). Neurotherapeutics 2007;4(2):233–237.